Indication for antiviral treatment according to the EASL guidelines for the treatment of chronic HBV infection (EASL 2017).
| HBeAg positive or negative chronic hepatitis B | HBV DNA >2,000 IU/mL, ALT ULN and/or at least moderate liver necroinflammation or fibrosis | Treatment |
| HBV DNA >20,000 IU/mL and ALT >2 x ULN regardless of fibrosis | ||
| HBeAg positive chronic infection | 30 years | |
| HBV infection and cirrhosis | Any detectable HBV DNA level | |
| Family history of HCC or cirrhosis; extrahepatic manifestations | Any detectable HBV DNA level | Treatment possible, even if typical indications not fulfilled |
| Special populations: | ||
| HBV infected individuals undergoing immunosuppression | HBsAg positive | ETV or TDF or TAF as prophylaxis* |
| HBsAg negative, anti-HBc positive | NA prophylaxis if high risk of HBV reactivation* | |
| HBV infection in pregnancy | NA treatment if benefit outweighs risk** |
Author Profile
Dr. D.Zeqiraj medical doctor at QKUK- Pristina, department of Infectious disease.